Seeking Alpha

More on Medicines Company Q4: FDA accepts NDA for antibiotic

  • The FDA has accepted Medicines Company's (MDCO +1.7%) filing of a new drug application (NDA) for the firm's Oritavancin intravenous antibiotic, with priority review, for the treatment of certain types of skin infections. (PR)
  • Q4 adjusted net income decreased 38% to $17.7M.
  • Total net income dropped to $1.2M from $20.7M.
  • Amortization of acquired intangible assets 10.1M.
  • During Q4, Medicines Company completed the acquisition of Rempex Pharmaceuticals and a co-promotion partnership with Boston Scientific. (PR)
  • Previous
From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs